BioMed Research International

Plasma Cell Neoplasms: Genetics, Pathobiology, and New Therapeutic Strategies


Publishing date
15 Aug 2014
Status
Published
Submission deadline
28 Mar 2014

Lead Editor

1Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul 110-744, Republic of Korea

2Nagoya City Higashi General Hospital, Wakamizu, Chikusa-Ku, Nagoya, Japan

3Cancer Science Institute of Singapore, NUS, Singapore


Plasma Cell Neoplasms: Genetics, Pathobiology, and New Therapeutic Strategies

Description

Plasma cell neoplasms are a phenotypically heterogeneous disorder with broad spectrum, including plasma cell myeloma, monoclonal gammopathy of unknown significance, and amyloidosis. Each plasma cell neoplasm is defined by diagnostic criteria, and accordingly therapeutic strategies are developed. Scientists often have a difficulty in discovering genetics of plasma cell neoplasms due to the sorting problem. Deep sequencing utilizing next generation sequencing or single cell genomics is expected to break through this barrier.

Since the introduction of bortezomib, novel therapeutic agents have led to the improvement of survival and novel tools to characterize the plasma cell neoplasms that provide better care to patients.

We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to understand the molecular pathology underlying plasma cell neoplasms, the design of strategies to treat these conditions, and the evaluation of outcomes. We are particularly interested in articles describing the changes in epidemiology, pathobiology of signal pathways, measuring outcomes from treatment trials, advances in molecular genetics and molecular diagnostics, new insights into plasma cell neoplasms using single cell genomics, siRNA, stem cell transplantation, and cytogenetics. Potential topics include, but are not limited to:

  • Genetic changes of plasma cell myeloma discovered by next generation sequencing
  • Epidemiology of plasma cell myeloma
  • New technics for plasma cell sorting
  • Cytogenetic changes that distinguish each plasma cell neoplasm
  • New therapeutic strategy for plasma cell myeloma
  • New parameters in accessing treatment response
  • Ethnic differences in the genetic changes of plasma cell neoplasms
  • Epidemiology of AL amyloidosis
  • New therapeutic trials for amyloidosis
  • Changing trends in epidemiology of monoclonal gammopathy of unknown significance
  • Therapeutic strategy for monoclonal gammopathy of unknown significance
  • Predictive factors for progression of MGUS to myeloma

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/hematology/plasm/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2014
  • - Article ID 941820
  • - Editorial

Plasma Cell Neoplasms: Genetics, Pathobiology, and New Therapeutic Strategies

Dong Soon Lee | Wee-Joo Chng | Kazuyuki Shimizu
  • Special Issue
  • - Volume 2014
  • - Article ID 510408
  • - Research Article

Establishment of Cell Lines from Both Myeloma Bone Marrow and Plasmacytoma: SNU_MM1393_BM and SNU_MM1393_SC from a Single Patient

Youngil Koh | Woo-June Jung | ... | Sung-Soo Yoon
  • Special Issue
  • - Volume 2014
  • - Article ID 437852
  • - Research Article

Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma

Sung Min Kim | Moon Jin Kim | ... | Chul Won Jung
  • Special Issue
  • - Volume 2014
  • - Article ID 232546
  • - Review Article

Implications of Heterogeneity in Multiple Myeloma

Sanjay de Mel | Su Hong Lim | ... | Wee-Joo Chng
  • Special Issue
  • - Volume 2014
  • - Article ID 636514
  • - Review Article

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma

Zhigang Xie | Wee Joo Chng
  • Special Issue
  • - Volume 2014
  • - Article ID 245247
  • - Clinical Study

Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study

Ki-Seong Eom | Seok Jin Kim | ... | Chang-Ki Min
  • Special Issue
  • - Volume 2014
  • - Article ID 717919
  • - Review Article

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma

P. J. Teoh | W. J. Chng
  • Special Issue
  • - Volume 2014
  • - Article ID 237698
  • - Clinical Study

The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients

Joo Young Jung | Ho Young Kim | ... | Hyo Jung Kim
  • Special Issue
  • - Volume 2014
  • - Article ID 893243
  • - Research Article

Expression of Myeloid Antigen in Neoplastic Plasma Cells Is Related to Adverse Prognosis in Patients with Multiple Myeloma

Hyoeun Shim | Joo Hee Ha | ... | Sun-Young Kong
  • Special Issue
  • - Volume 2014
  • - Article ID 253243
  • - Research Article

Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea

Ho Sup Lee | Kihyun Kim | ... | Chang-Ki Min
BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision67 days
Acceptance to publication30 days
CiteScore3.600
Impact Factor2.276
 Submit